Article

Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging.

Molecular Imaging Laboratory, Department of Radiology, University of Pittsburgh School of Medicine, 100 Technology Drive Suite 452G, Pittsburgh, PA 15219; USA. .
Current Medicinal Chemistry (Impact Factor: 3.72). 08/2012; DOI: 10.2174/092986712803341467
Source: PubMed

ABSTRACT Receptor-targeted optical imaging of cancer is emerging as an attractive strategy for early cancer diagnosis and surgical guidance. The success of such strategy depends largely upon the development of receptor-targeted fluorescent probes with high specificity and binding affinity to the target receptors. Recently, a host of such probes have been reported to target cancer-specific receptors, such as somatostatin receptors (SSTRs), integrin receptors, cholecystokinin-2 (CCK2) receptor, gastrin-releasing peptide (GRP) receptor, endothelin A (ETA) receptor, translocator protein (TSPO) receptor, epidermal growth factor (EGF) receptor, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF) receptor, folate receptor (FR), transferrin receptor (TFR), low-density lipoprotein (LDL) receptors, type I insulin-like growth factor receptor (IGF1R), vasoactive intestinal peptide (VIP) receptors, urokinase plasminogen activator (uPA) and estrogen receptor (ER). This review will describe the recent advances in synthetic targeting optical imaging probes and demonstrate their in vivo imaging potentials. Moreover, current status of near infrared (NIR) fluorescent dyes, targeting moieties and coupling reactions, as well as strategies for designing targeted probes, will also be discussed.

2 Bookmarks
 · 
502 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The type 2 cannabinoid receptor (CB2R) plays a vital role in carcinogenesis and progression, and is emerging as a therapeutic target for cancers. However, the exact role of CB2R in cancer progression and therapy remains unclear. This has driven the increasing efforts of studying CB2R and cancers using molecular imaging tools. In addition, many types of cancers over-express CB2R, and the expression levels of CB2R appear to be associated with tumor aggressiveness. Such up-regulation of the receptor in cancer cells provides opportunities in CB2R-targeted imaging with high contrast and therapy with low side effects. In the present study, we report the first in vivo tumor-targeted optical imaging using a novel CB2R-targeted near infrared probe. In vitro cell fluorescent imaging and competitive binding assay indicated specific binding of NIR760-mbc94 to CB2R in CB2-mid delayed brain tumor (DBT) cells. NIR760-mbc94 also preferentially labeled CB2-mid DBT tumors in vivo, with a 3.7-fold tumor to background contrast enhancement at 72 h post injection, whereas the fluorescence signal from the tumors of the mice treated with NIR760 free dye was nearly at background level at the same time point. SR144528, as the CB2R competitor, significantly inhibited tumor uptake of NIR760-mbc94, indicating that NIR760-mbc94 binds to CB2R specifically. In summary, NIR760-mbc94 specifically binds to CB2R in vitro and in vivo, and appears to be a promising molecular tool that may have great potential in diagnostic imaging of CB2R positive cancers, therapeutic monitoring, as well as elucidating the role of CB2R in cancer progression and therapy.
    Bioconjugate Chemistry 10/2013; · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The design and development of radiolabelled steroid derivatives has been an important area of research due to their well-known value in breast cancer targeting. The estrogen receptor (ER) and progesterone receptor (PR) are important biomarkers in the diagnosis, prognosis and follow-up of the therapeutic response of breast tumours. Thus, several radioligands based on estrogens and progestins have been proposed for targeted functional ER imaging. The aim of this review is to survey and analyze the developments in this field, which have led to the design of a number of PET steroid-based imaging agents, a few of which seem to be promising as radiopharmaceuticals for detection of ER-positive breast tumours.
    Current Medicinal Chemistry 12/2012; · 3.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although mainly developed for preclinical research and therapeutic use, antibodies have high antigen specificity, which can be used as a courier to selectively deliver a diagnostic probe or therapeutic agent to cancer. It is generally accepted that the optimal antigen for imaging will depend on both the expression in the tumor relative to normal tissue and the homogeneity of expression throughout the tumor mass and between patients. For the purpose of diagnostic imaging, novel antibodies can be developed to target antigens for disease detection, or current FDA-approved antibodies can be repurposed with the covalent addition of an imaging probe. Reuse of therapeutic antibodies for diagnostic purposes reduces translational costs since the safety profile of the antibody is well defined and the agent is already available under conditions suitable for human use. In this review, we will explore a wide range of antibodies and imaging modalities that are being translated to the clinic for cancer identification and surgical treatment.
    Cancer and metastasis reviews 06/2014; · 7.79 Impact Factor

Full-text

View
2,448 Downloads
Available from
May 23, 2014